Arvaya Healthcare Ltd
Incorporated in 1985, Bijoy Hans Ltd offers medical and lifestyle solutions through physical infrastructure and digital platforms.[1]
- Market Cap ₹ 523 Cr.
- Current Price ₹ 109
- High / Low ₹ 145 / 47.7
- Stock P/E 342
- Book Value ₹ 13.1
- Dividend Yield 0.00 %
- ROCE 2.62 %
- ROE 2.70 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 198 days to 123 days
Cons
- Stock is trading at 8.30 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.29%
- Promoter holding is low: 28.3%
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.1.40 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 0.28 | 9.11 | |
| Sales growth | +3,153.57% | |
| 0.80 | 8.37 | |
| Operating Profit | -0.52 | 0.74 |
| OPM % | -185.71% | 8.12% |
| 0.75 | 1.40 | |
| Interest | 0.01 | 0.43 |
| Depreciation | 0.02 | 0.62 |
| Profit before tax | 0.20 | 1.09 |
| Tax % | 30.00% | 17.43% |
| 0.14 | 0.90 | |
| EPS in Rs | 0.47 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 3154% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 291% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 74% |
| 1 Year: | 128% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 3.00 | 48.02 |
| Reserves | 0.53 | 15.05 |
| 0.00 | 49.38 | |
| 0.06 | 28.17 | |
| Total Liabilities | 3.59 | 140.62 |
| 0.00 | 92.04 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.13 | 0.16 |
| 3.46 | 48.42 | |
| Total Assets | 3.59 | 140.62 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 0.22 | -3.28 | |
| 0.92 | -5.58 | |
| -0.06 | 8.50 | |
| Net Cash Flow | 1.08 | -0.36 |
| Free Cash Flow | 1.14 | -7.94 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -48% | -443% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 0.00 | 88.14 |
| Inventory Days | 0.00 | 546.06 |
| Days Payable | 3,279.25 | |
| Cash Conversion Cycle | 0.00 | -2,645.04 |
| Working Capital Days | 273.75 | 122.60 |
| ROCE % | 2.62% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expenses (Headcount Proxy) Rupees ・Standalone data |
|
||||||||||
| Interest Income on Deposits Rupees ・Standalone data |
|||||||||||
| Non-Current Investments (Investment Portfolio) Rupees ・Standalone data |
|||||||||||
| Trade Receivables Rupees ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th September 2026
- Q2 FY27 results approved; acquisition of SIGPL completed on 1 Nov 2026, rights issue proposed up to ₹21,000 lakh.
-
Statement Of Deviation And Variation For The Quarter Ended 30Th September 2026
- Statement of deviation/variation not applicable for quarter ended 30 September 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 13Th November 2026
- Board approved Q2 FY26 results; completed acquisition of SIGPL on 1 Nov 2026 and opened trading window 16 Nov.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Revision in intimation and In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya Healthcare Limited (formerly known …
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
BHL is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics, and investments.